NANO Nanobiotix SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Nov. 14, 2025 (GLOBE NEWSWIRE) --

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO:FP

Reuters: NANO.PA

Website:

DateNumber of Shares

Outstanding		Total number of voting rights
Total voting rights,

theoretical1		Total voting rights,

exercisable2
October 31, 202548,237,47150,267,96250,245,844



About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and .

_________________

1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Contacts

Nanobiotix
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835



Investor Relations Department

Joanne Choi

VP, Investor Relations (US)

+1 (713) 609-3150



Ricky Bhajun

Director, Investor Relations (EU)







Media Relations


France – HARDY

Caroline Hardy

50



  

Global – uncapped

Becky Lauer

+1 (646) 286-0057





Attachment



EN
14/11/2025

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Jean-François Granjon
  • Louis Boujard
  • CFA
ISP INTESA SANPAOLO S.P.A.
NANO NANOBIOTIX SA
ADVI ADVINI
UCG UNICREDIT S.P.A.
FLU FLUGHAFEN WIEN AG
AXS ACCSYS TECHNOLOGIES
ALHAF HAFFNER ENERGY SA
ORP ORPEA
1h / 58m 1h / 58m 1 EN
Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Jean-François Granjon
  • Louis Boujard
  • CFA
ISP INTESA SANPAOLO S.P.A.
NANO NANOBIOTIX SA
ADVI ADVINI
UCG UNICREDIT S.P.A.
FLU FLUGHAFEN WIEN AG
AXS ACCSYS TECHNOLOGIES
ALHAF HAFFNER ENERGY SA
ORP ORPEA
2h / 4m 2h / 4m 1 FR
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
NANO NANOBIOTIX SA

Nanobiotix : The latest clinical data underpin the investment case

The recent data (phase 1) in melanoma, pancreatic cancer and head and neck cancer with anti-PD1 (first or second line) reinforce, in our opinion, the local action as well as the systemic action of JNJ-1900/NBTXR3. These results confirm what has already been observed in previous clinical studies and support the hypothesis that the candidate drug could become a "backbone therapy" in oncology. The risk-reward profile looks particularly attractive at these valuation levels. We reiterate our Outperfo...

4h / 34m 4h / 34m 1 EN
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
NANO NANOBIOTIX SA

Nanobiotix : Les dernières données cliniques renforcent la thèse d’inv...

Les données récentes (phase 1) dans le mélanome, le cancer du pancréas ou le cancer de la tête et du cou avec anti-PD1 (1e ou 2nd L) renforcent, selon nous, l’action locale ainsi que l’action systémique de JNJ-1900/NBTXR3. Ces résultats confirment ce qui a déjà été observé dans les précédentes études cliniques et soutiennent la thèse selon laquelle le candidat médicament pourrait devenir une « backbone therapy » en oncologie. Le risk/reward nous semble particulièrement attractif sur ces niveaux ...

4h / 40m 4h / 40m 1 FR
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --   (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the mar...

December 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch